Quest PharmaTech Inc - Asset Resilience Ratio
Quest PharmaTech Inc (QPT) has an Asset Resilience Ratio of 0.00% as of January 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Quest PharmaTech Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2021)
This chart shows how Quest PharmaTech Inc's Asset Resilience Ratio has changed over time. See Quest PharmaTech Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Quest PharmaTech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see QPT stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Quest PharmaTech Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Quest PharmaTech Inc Industry Peers by Asset Resilience Ratio
Compare Quest PharmaTech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Quest PharmaTech Inc (2017–2021)
The table below shows the annual Asset Resilience Ratio data for Quest PharmaTech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-01-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$175.61 Million ≈ $127.04 Million |
-- |
| 2020-01-31 | 6.74% | CA$300.00K ≈ $217.02K |
CA$4.45 Million ≈ $3.22 Million |
-46.85pp |
| 2019-01-31 | 53.59% | CA$3.11 Million ≈ $2.25 Million |
CA$5.81 Million ≈ $4.20 Million |
-31.49pp |
| 2018-01-31 | 85.08% | CA$10.88 Million ≈ $7.87 Million |
CA$12.78 Million ≈ $9.25 Million |
+12.28pp |
| 2017-01-31 | 72.80% | CA$8.27 Million ≈ $5.99 Million |
CA$11.37 Million ≈ $8.22 Million |
-- |
About Quest PharmaTech Inc
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.